Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -327.8%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $370762 | $1M | $2M | $5M | $12M | $64M | — | — | — |
| Enterprise Value | $-6241275 | $-5415392 | $324593 | $2M | $-2962363 | $40M | — | — | — |
| P/E Ratio → | -0.03 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.19 | 0.62 | 0.20 | 0.46 | 1.17 | 5.73 | — | — | — |
| P/B Ratio | 0.10 | 0.39 | 0.57 | 0.46 | 0.60 | 2.14 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -2.81 | 0.03 | 0.24 | -0.28 | 3.55 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 1.2% | 1.2% | 42.9% | 51.4% | 54.3% | 52.9% | 56.2% | 50.5% | 46.2% |
| Operating Margin | -465.4% | -465.4% | -137.0% | -112.5% | -97.9% | -53.2% | -29.4% | -90.3% | -76.4% |
| Net Profit Margin | -543.7% | -543.7% | -134.5% | -111.8% | -98.5% | -80.5% | -56.8% | -110.0% | -121.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -327.8% | -327.8% | -191.5% | -73.9% | -40.9% | -713.1% | — | — | — |
| ROA | -111.1% | -111.1% | -99.3% | -54.9% | -34.0% | -42.7% | -89.3% | -114.5% | -132.2% |
| ROIC | — | — | -204.4% | -131.1% | -143.3% | — | — | — | — |
| ROCE | -261.0% | -261.0% | -190.7% | -74.2% | -38.0% | -68.5% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.09 | 0.02 | 0.01 | 0.11 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.14 | -0.47 | -0.22 | -0.74 | -0.82 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -5375.89 | -5375.89 | -57.58 | -47.09 | -41.88 | -3.26 | -1.22 | -1.83 | -3.51 |
Net cash position: cash ($7M) exceeds total debt ($268798)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | 1.12 | 0.62 | 1.36 | 4.60 | 13.15 | 0.16 | 0.10 | 0.20 |
| Quick Ratio | 1.12 | 1.12 | 0.62 | 1.36 | 4.60 | 13.15 | 0.16 | 0.10 | 0.20 |
| Cash Ratio | 1.10 | 1.10 | 0.33 | 0.83 | 3.58 | 11.07 | 0.03 | 0.00 | 0.10 |
| Asset Turnover | — | 0.20 | 0.99 | 0.63 | 0.42 | 0.31 | 1.32 | 1.02 | 1.09 |
| Inventory Turnover | — | — | — | — | — | — | — | 38.75 | 49.96 |
| Days Sales Outstanding | — | 9.14 | 56.75 | 108.12 | 137.75 | 160.04 | 105.19 | 118.26 | 85.20 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $115062 | $17771 | $11302 | $11055 | $10216 | $1170 | $1170 | $1171 |
Existential liquidity and solvency
Based on reported financial data, iSpecimen's P/S ratio of 0.19 suggests the market has largely abandoned growth expectations, pricing the firm as a distressed asset rather than a viable technology platform following the severe revenue contraction observed in recent quarterly filings.
The lack of meaningful P/E or EV/EBITDA multiples underscores the absence of positive earnings power, leaving investors to focus solely on the liquidation value of the balance sheet. This valuation level implies that the market views the company's proprietary digital integration as having negligible residual value in the absence of transaction volume.
As reported in financial statements, iSpecimen's ROIC has consistently trended into deep negative territory, reaching -181.3% in 2025Q2, which indicates that the company is destroying shareholder capital at an accelerating rate rather than compounding it through its marketplace operations.
The persistent inability to generate positive returns on invested capital suggests that the company's cost structure is fundamentally misaligned with its revenue-generating capacity. Investors should monitor whether management can stabilize these returns, though current trends suggest a structural decay that is difficult to reverse without a complete business model pivot.
According to historical data, the company's DPO has reached extreme levels, such as 5368 days in 2026Q1, which suggests that iSpecimen is relying heavily on extended supplier payment terms to manage its dwindling cash position rather than operational efficiency.
The erratic nature of the cash conversion cycle, combined with extremely low asset turnover, indicates that the marketplace model is failing to achieve the velocity required for self-sustainability. This reliance on supplier credit appears to be a stop-gap measure that may mask deeper liquidity issues as the company struggles to process transactions.
Based on recent SEC filings, the current ratio has deteriorated to 0.62 as of 2026Q1, signaling that the company's liquid assets are insufficient to cover its short-term liabilities, thereby increasing the risk of a liquidity crisis in the near term.
The rapid erosion of the current ratio from 1.36 in 2023Q4 highlights the impact of persistent operational cash burn on the company's financial flexibility. Without a significant infusion of capital or a drastic reduction in overhead, the company's ability to meet its obligations appears increasingly vulnerable to further revenue volatility.
Investors frequently misapply standard marketplace revenue multiples to iSpecimen, failing to account for the fact that the company's gross margins are near zero, which renders traditional P/S valuation metrics largely irrelevant for assessing the firm's true economic value.
Because the company acts more as a low-margin broker than a high-margin software platform, revenue figures are inflated by pass-through costs that do not contribute to profitability. Analysts should instead focus on net commission revenue or contribution margin to understand the actual value-add of the platform, as the current P/S ratio obscures the underlying lack of sustainable earning power.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ISPC stock.
iSpecimen Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
iSpecimen Inc.'s return on equity (ROE) is -327.8%. The historical average is -158.5%.
Based on historical data, iSpecimen Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
iSpecimen Inc. has 1.2% gross margin and -465.4% operating margin.